Curant Rare and IntraBio Bring Real-World Evidence to Niemann-Pick Disease Type C Care

by Tim Griffin | Jun 16, 2026

Curant Rare and IntraBio Bring Real-World Evidence to Niemann-Pick Disease Type C Care Real-world data is essential to understanding how therapies perform beyond clinical trials, particularly in rare diseases like Niemann-Pick disease type C (NPC). As healthcare...

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products  

by Tim Griffin | Jan 22, 2026

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products Atlanta, GA – Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide...

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

by Tim Griffin | Oct 1, 2025

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics ATLANTA–(BUSINESS WIRE)–Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated...

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half

by Tim Griffin | Aug 18, 2025

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half Atlanta, GA – August 18, 2025 – Curant Health is proud to announce that Curant...

Curant Health Launches Curant Rare™, A Specialized Division Dedicated to Rare & Orphan Disease Care

by Tim Griffin | Feb 7, 2025

Curant Rare Selected By IntraBio as the Exclusive Specialty Pharmacy for AQNEURSA™ (levacetylleucine), the First Stand-Alone Therapy for Niemann-Pick Disease Type C ATLANTA–(BUSINESS WIRE)–Curant Health, a multifaceted Medication Care...